| PD-L2 is a second ligand for PD-1 and inhibits T cell activation Y Latchman, CR Wood, T Chernova, D Chaudhary, M Borde, I Chernova, ... Nature immunology 2 (3), 261-268, 2001 | 3862 | 2001 |
| Molecular and biochemical aspects of the PD-1 checkpoint pathway VA Boussiotis New England Journal of Medicine 375 (18), 1767-1778, 2016 | 1428 | 2016 |
| Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation GJ Freeman, JG Gribben, VA Boussiotis, JW Ng, VA Restivo Jr, ... Science 262 (5135), 909-911, 1993 | 1310 | 1993 |
| PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation N Patsoukis, K Bardhan, P Chatterjee, D Sari, B Liu, LN Bell, ED Karoly, ... Nature communications 6 (1), 6692, 2015 | 1166 | 2015 |
| B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4 GJ Freeman, VA Boussiotis, A Anumanthan, GM Bernstein, XY Ke, ... Immunity 2 (5), 523-532, 1995 | 750 | 1995 |
| Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation N Patsoukis, J Brown, V Petkova, F Liu, L Li, VA Boussiotis Science signaling 5 (230), ra46-ra46, 2012 | 646 | 2012 |
| The PD1: PD-L1/2 pathway from discovery to clinical implementation K Bardhan, T Anagnostou, VA Boussiotis Frontiers in immunology 7, 550, 2016 | 628 | 2016 |
| Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells AJ McAdam, TT Chang, AE Lumelsky, EA Greenfield, VA Boussiotis, ... The Journal of Immunology 165 (9), 5035-5040, 2000 | 612 | 2000 |
| IL-10–producing T cells suppress immune responses in anergic tuberculosis patients VA Boussiotis, EY Tsai, EJ Yunis, S Thim, JC Delgado, CC Dascher, ... The Journal of clinical investigation 105 (9), 1317-1325, 2000 | 577 | 2000 |
| Transplantation of anergic histoincompatible bone marrow allografts EC Guinan, VA Boussiotis, D Neuberg, LLV Brennan, N Hirano, ... New England Journal of Medicine 340 (22), 1704-1714, 1999 | 564 | 1999 |
| CTLA-4 regulates induction of anergy in vivo RJ Greenwald, VA Boussiotis, RB Lorsbach, AK Abbas, AH Sharpe Immunity 14 (2), 145-155, 2001 | 563 | 2001 |
| Reconstructing and deconstructing agonist-induced activation of integrin αIIbβ3 J Han, CJ Lim, N Watanabe, A Soriani, B Ratnikov, DA Calderwood, ... Current Biology 16 (18), 1796-1806, 2006 | 561 | 2006 |
| Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1 VA Boussiotis, GJ Freeman, A Berezovskaya, DL Barber, LM Nadler Science 278 (5335), 124-128, 1997 | 526 | 1997 |
| RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion EM Lafuente, AAFL van Puijenbroek, M Krause, CV Carman, GJ Freeman, ... Developmental cell 7 (4), 585-595, 2004 | 507 | 2004 |
| Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity EC Guinan, JG Gribben, VA Boussiotis, GJ Freeman, LM Nadler | 505 | 1994 |
| T cell anergy and costimulation LJ Appleman, VA Boussiotis Immunological reviews 192 (1), 161-180, 2003 | 493 | 2003 |
| The complex role of tumor-infiltrating macrophages A Christofides, L Strauss, A Yeo, C Cao, A Charest, VA Boussiotis Nature immunology 23 (8), 1148-1156, 2022 | 456 | 2022 |
| The role of peroxisome proliferator-activated receptors (PPAR) in immune responses A Christofides, E Konstantinidou, C Jani, VA Boussiotis Metabolism 114, 154338, 2021 | 450 | 2021 |
| Revisiting the PD-1 pathway N Patsoukis, Q Wang, L Strauss, VA Boussiotis Science advances 6 (38), eabd2712, 2020 | 449 | 2020 |
| CTLA4 mediates antigen-specific apoptosis of human T cells. JG Gribben, GJ Freeman, VA Boussiotis, P Rennert, CL Jellis, ... Proceedings of the National Academy of Sciences 92 (3), 811-815, 1995 | 418 | 1995 |
